scholarly journals Changes in plasma C1q, apelin and adropin concentrations in older adults after descending and ascending stair walking intervention

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Trevor C. Chen ◽  
Tsang-Hai Huang ◽  
Wei-Chin Tseng ◽  
Kuo-Wei Tseng ◽  
Chung-Chan Hsieh ◽  
...  
Keyword(s):  
Outcome Measures ◽  
Training Session ◽  
Blood Lipid ◽  
Tolerance Test ◽  
Knee Extensors ◽  
Oral Glucose ◽  
Obese Women ◽  
Maximal Voluntary Isometric Contraction ◽  
Walking Intervention ◽  
Stair Walking

AbstractThis study compared changes in plasma complement component 1q (C1q), apelin and adropin concentrations in older obese women after descending (DSW) and ascending stair walking (ASW) training (n = 15/group) performed twice a week for 12 weeks, with gradual increases in exercise time from 5 to 60 min. Fasting blood samples were collected 3 days before the first and 4 days after the last training session. The improvements in the maximal voluntary isometric contraction (MVIC) strength of the knee extensors, functional physical fitness [e.g., 30-s chair stand (CS) performance], resting systolic blood pressure (SBP), insulin sensitivity [e.g., oral glucose tolerance test (OGTT)] and blood lipid profiles [e.g., total cholesterol (TC)] were greater (p < 0.05) in the DSW than ASW group. Plasma C1q decreased (− 51 ± 30%), and apelin (23 ± 15%) and adropin (127 ± 106%) increased (p ≤ .0.05) only after DSW. Significant (p ≤  0.01) partial correlations were found between the pre- to post-DSW changes in C1q, apelin or adropin and changes in outcome measures [e.g., C1q and MVIC (r = − 0.837), apelin and SBP (r = − 0.854), and andropin and OGTT (r = − 0.729)]. These results showed that greater decreases in plasma C1q and greater increases in apelin and adropin concentrations were associated with greater improvements in outcome measures after DSW than after ASW.

scholarly journals Circulating obestatin levels and the ghrelin/obestatin ratio in obese women

2007 ◽  
Vol 157 (3) ◽  
pp. 295-301 ◽  
Author(s):  
Valentina Vicennati ◽  
Silvia Genghini ◽  
Rosaria De Iasio ◽  
Francesca Pasqui ◽  
Uberto Pagotto ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Tolerance Test ◽  
Normal Weight ◽  
Metabolic Parameters ◽  
Blood Levels ◽  
Oral Glucose ◽  
Sensitivity Index ◽  
Model Assessment ◽  
Obese Women ◽  
Glucose Levels

Objective: We measured blood levels of obestatin, total ghrelin, and the ghrelin/obestatin ratio and their relationship with anthropometric and metabolic parameters, adiponectin and insulin resistance, in overweight/obese and normal-weight women. Design: Outpatients Unit of Endocrinology of the S Orsola-Malpighi Hospital of Bologna, Italy. Methods: Fasting obestatin, ghrelin, adiponectin and lipid levels, fasting and glucose-stimulated oral glucose tolerance test insulin, and glucose levels were measured in 20 overweight/obese and 12 controls. The fasting ghrelin/obestatin ratio was calculated; the homeostasis model assessment-IR (HOMA-IR) and insulin sensitivity index (ISIcomposite) were calculated as indices of insulin resistance. Results: Obese women had higher obestatin and lower ghrelin blood levels, and a lower ghrelin/obestatin ratio compared with controls. In all subjects, obestatin was significantly and positively correlated with total cholesterol and triglycerides, but not with ghrelin, anthropometric, and metabolic parameters. In the obese women, however, obestatin and ghrelin concentrations were positively correlated. By contrast, the ghrelin/obestatin ratio was significantly and negatively correlated with body mass index, waist, waist-to-hip ratio, fasting insulin, and HOMA-IR, and positively with ISIcomposite but not with adiponectin. None of these parameters were correlated with the ghrelin/obestatin ratio in the obese. Conclusions: Increased obestatin, decreased ghrelin levels, and a decreased ghrelin/obestatin ratio characterize obesity in women. This supports the hypothesis that the imbalance of ghrelin and obestatin may have a role in the pathophysiology of obesity. On the other hand, some relevant differences between our data on circulating levels of obestatin and the ghrelin/obestatin ratio in obese subjects and those reported in the few studies published so far imply that further research is needed.

scholarly journals Antidiabetic Effect of Methanolic Extract fromBerberis julianaeSchneid. via Activation of AMP-Activated Protein Kinase in Type 2 Diabetic Mice

2014 ◽  
Vol 2014 ◽  
pp. 1-12 ◽  
Author(s):  
Jing Yang ◽  
Ping Zhao ◽  
Dingrong Wan ◽  
Qi Zhou ◽  
Chao Wang ◽  
...  
Keyword(s):  
Body Weight ◽  
Methanolic Extract ◽  
Blood Lipid ◽  
Tolerance Test ◽  
Oral Glucose ◽  
Oral Glucose Tolerance ◽  
Glut4 Translocation ◽  
Antidiabetic Effect ◽  
Amp Activated Protein Kinase

We have investigated the antidiabetic effect and mechanism of methanolic extract ofBerberis julianaeSchneid. (BJSME) in STZ induced Type 2 diabetes mellitus mice. T2DM mice were induced by high fat diet and low dose streptozotocin (STZ). BJSME was orally administrated at the doses of 60, 120, and 240 mg/kg/d, for 21 days. Metformin was used as positive control drug. Food intake, body weight, plasma glucose, oral glucose tolerance test, insulin tolerance test, insulin, and blood-lipid content were measured. The effects of BJSME on the glucose transporter 4 (GLUT4) translocation in L6 myotubes and the GLUT4 protein expression in skeletal muscle as well as phosphorylation of the AMP-activated protein kinase (AMPK) in liver and muscle were examined.In vitroandin vivoresults indicate that BJSME increased GLUT4 translocation by 1.8-fold and BJSME significantly improved the oral glucose tolerance and low density lipoprotein cholesterol (LDL-C) of serum and reduced body weight, glucose, and other related blood-lipid contents. The BJSME treatment also stimulated the phosphorylation of AMPK. Thus, BJSME seems to possess promising beneficial effects for the treatment of T2DM with the possible mechanism via stimulating AMPK activity.

Cortisol Levels During an Oral Glucose Tolerance Test in Lean and Obese Women

2005 ◽  
Vol 31 (3) ◽  
pp. 213-218 ◽  
Author(s):  
Mehtap Cakir ◽  
Ramazan Sari ◽  
Ozgur Tosun ◽  
Umit Karayalcin
Keyword(s):  
Glucose Tolerance ◽  
Oral Glucose Tolerance Test ◽  
Glucose Tolerance Test ◽  
Tolerance Test ◽  
Oral Glucose ◽  
Obese Women ◽  
Oral Glucose Tolerance ◽  
Cortisol Levels

Persistence of hyperinsulinemia in polycystic ovary syndrome after ovarian suppression by gonadotropin-releasing hormone agonist

1992 ◽  
Vol 126 (2) ◽  
pp. 132-136 ◽  
Author(s):  
Per Olav Dale ◽  
Tom Tanbo ◽  
Ole Djøseland ◽  
Jak Jervell ◽  
Thomas Åbyholm
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Glucose Tolerance ◽  
Glucose Tolerance Test ◽  
Polycystic Ovary ◽  
Tolerance Test ◽  
Oral Glucose ◽  
Obese Women ◽  
Oral Glucose Tolerance ◽  
Ovary Syndrome ◽  
Gonadotropin Releasing Hormone Agonist

To investigate the effect of long-term androgen suppression on insulin sensitivity, obese and non-obese women with the polycystic ovary syndrome and obese and non-obese ovulatory women were given an oral glucose tolerance test before and after treatment with a gonadotropin-releasing hormone agonist. The women with polycystic ovary syndrome showed higher basal luteinizing hormone and androgen levels than the ovulatory women. All women with the polycystic ovary syndrome responded non-diabetically to the glucose tolerance test. However, compared with controls, the obese women with the polycystic ovary syndrome showed a hyperinsulinemic response to the glucose tolerance test, indicating insulin resistance. During the 3-h glucose tolerance test there was no concomitant change in androgen levels in the hyperinsulinemic women with the polycystic ovary syndrome. The insulin response to an oral glucose tolerance test remained unchanged in all women, although a hypogonadotropic hypogonadal state was maintained for several weeks. This study therefore suggests that endogenous androgens do not play a role in sustaining insulin resistance in women with the polycystic ovary syndrome.

Impaired superficial femoral artery vasodilation and leg blood flow in young obese women following an oral glucose tolerance test

2012 ◽  
Vol 37 (1) ◽  
pp. 176-183 ◽  
Author(s):  
T.D. Olver ◽  
T.J. Hazell ◽  
C.D. Hamilton ◽  
J.K. Shoemaker ◽  
P.W.R. Lemon
Keyword(s):  
Blood Flow ◽  
Glucose Tolerance ◽  
Young Women ◽  
Femoral Artery ◽  
Superficial Femoral Artery ◽  
Tolerance Test ◽  
Oral Glucose ◽  
Obese Women ◽  
Leg Blood Flow ◽  
Glucose Ingestion

This study was designed to test the hypothesis that glucose ingestion following an overnight fast increases leg vascular conductance (LVCd) and superficial femoral artery (SFA) vasodilation in lean but not obese young women. Obese (23.5 ± 4.0 years, 84.7 ± 14.7 kg, 37.2% ± 6.4% fat; mean ± SD, n = 8) and lean (23.8 ± 2.4 years, 60.6 ± 4.0 kg, 22.3% ± 2.8% fat; n = 8) women arrived in the laboratory at 0830 h after a 12-h overnight fast for body composition (densitometry) assessment. Then, capillary blood glucose (BGlu), plasma insulin, heart rate, cardiac output, mean arterial pressure, leg blood flow (Doppler ultrasound), and LVCd were measured (after 15 min in the supine position), and at 30-min intervals for 2 h following glucose ingestion (75 g glucose load, 12.5% solution). Fasting BGlu concentration was not different between groups (obese = 5.1 ± 0.47 vs. lean = 4.9 ± 0.37 mmol·L–1, p = 0.71) but 60, 90, and 120 min postingestion BGlu was elevated (p ≤ 0.03) in the obese women. Insulin differences were not significant. Fasting LVCd was not different between groups (lean = 0.72 ± 0.49 vs. obese = 0.70 ± 0.19 mL·min–1·mm Hg–1; p = 0.48); however, LVCd, as well as Δ in SFA diameter were significantly elevated (p ≤ 0.04) in the lean compared with the obese group at 60, 90, and 120 min postglucose ingestion (LVCd, peak lean = 1.4 ± 0.5 vs. peak obese = 0.8 ± 0.1 mL·min–1·mm Hg–1; Δ in SFA, peak lean = 0.51 ± 0.30 vs. peak obese = 0.09 ± 0.45 mm). The reduced LVCd following glucose ingestion could contribute to impaired glucose tolerance. Further, the lack of SFA dilation may be evidence of impaired vascular insulin responsiveness in these obese young women.

Cardiometabolic Effects of a Workplace Cycling Intervention

2019 ◽  
Vol 16 (7) ◽  
pp. 547-555 ◽  
Author(s):  
James E. Peterman ◽  
Kalee L. Morris ◽  
Rodger Kram ◽  
William C. Byrnes
Keyword(s):  
Physical Activity ◽  
Risk Factors ◽  
Cardiometabolic Risk ◽  
Intervention Group ◽  
Density Lipoprotein ◽  
Blood Lipid ◽  
Tolerance Test ◽  
Cardiometabolic Risk Factors ◽  
Oral Glucose ◽  
Blood Lipid Profile

Background: In laboratory settings, cycling workstations improve cardiometabolic risk factors. Our purpose was to quantify risk factors following a cycling intervention in the workplace. Methods: Twenty-one office workers who sat at work ≥6 hours per day underwent baseline physiological measurements (resting blood pressure, blood lipid profile, maximum oxygen consumption [], body composition, and 2-h oral glucose tolerance test). Participants were randomly assigned to a 4-week intervention only group (n = 12) or a delayed intervention group (n = 9) that involved a 4-week control condition before beginning the intervention. During the intervention, participants were instructed to use the cycling device a minimum of 15 minutes per hour, which would result in a total use of ≥2 hours per day during the workday. Following the intervention, physiological measurements were repeated. Results: Participants averaged 1.77 (0.48) hours per day of cycling during the intervention with no changes in actigraphy-monitored noncycling physical activity. Four weeks of the workplace intervention increased (2.07 [0.44] to 2.17 [0.44] L·min−1, P < .01); end of test power output (166.3 [42.2] to 176.6 [46.1] W, P < .01); and high-density lipoprotein cholesterol (1.09 [0.17] to 1.17 [0.24] mmol·L−1, P = .04). Conclusions: A stationary cycling device incorporated into a sedentary workplace for 4 weeks improves some cardiometabolic risk factors with no compensatory decrease in noncycling physical activity.

scholarly journals Influence of GDM Diagnosis and Treatment on Weight Gain, Dietary Intake and Physical Activity in Pregnant Women with Obesity: Secondary Analysis of the UPBEAT Study

Nutrients ◽  
2020 ◽  
Vol 12 (2) ◽  
pp. 359 ◽  
Author(s):  
La’Shay Atakora ◽  
Lucilla Poston ◽  
Louise Hayes ◽  
Angela C. Flynn ◽  
Sara L. White
Keyword(s):  
Physical Activity ◽  
Weight Gain ◽  
Dietary Intake ◽  
Pregnant Women ◽  
Secondary Analysis ◽  
Health Behaviours ◽  
Tolerance Test ◽  
Oral Glucose ◽  
Obese Women ◽  
Iadpsg Criteria

Obesity during pregnancy is associated with the development of gestational diabetes (GDM). This study aimed to assess if the result of an oral glucose tolerance test (OGTT) for GDM influences health (diet and physical activity) behaviours of pregnant women with obesity. In total, 1031 women who participated in the UK Pregnancies Better Eating and Activity Trial (UPBEAT) of a lifestyle intervention from early pregnancy were included. Changes in weight gain, dietary intake and physical activity following an OGTT undertaken between 27+0 and 28+6 weeks’ and 34 and 36 weeks’ gestation were examined using linear regression with appropriate adjustment for confounders. Obese women without GDM (IADPSG criteria) gained 1.9 kg (95% CI −2.2, −1.5, p < 0.001) more weight than women with GDM. Women with GDM demonstrated greater reductions in energy (–142kcal, 95%CI −242.2, −41.9, p = 0.006), carbohydrate intake (−1.5%E 95%CI –2.8, −0.3, p = 0.016) and glycaemic load (–15.2, 95%CI −23.6, –6.7, p < 0.001) and a greater increase in protein intake (2%E, 95%CI 1.3, 2.7, p < 0.001), compared to women without GDM. Trial intervention allocation did not influence any associations observed. The findings emphasise the need for strategies to optimise the health behaviours of pregnant women with obesity, following a negative OGTT for GDM.

scholarly journals Impact of abdominal fat and insulin resistance on arterial hypertension in non-obese women

2009 ◽  
Vol 53 (3) ◽  
pp. 340-343 ◽  
Author(s):  
Eliana A. Silva ◽  
Fernando Flexa ◽  
Maria Teresa Zanella
Keyword(s):  
Insulin Resistance ◽  
Arterial Hypertension ◽  
Fat Distribution ◽  
Tolerance Test ◽  
Abdominal Fat ◽  
Oral Glucose ◽  
Obese Women ◽  
Distribution Index ◽  
Central Fat ◽  
The Impact

OBJECTIVE: To evaluate the impact of abdominal fat and insulin resistance on arterial hypertension of non-obese women. METHODS:Thirty-five non-obese women (NO), age 35-68 years were studied, and divided into two groups according to the presence of hypertension (BP > 140 x 90 mmHg) ( HT = hypertensive; NT = normotensive). Leptin measurement and oral glucose tolerance test (OGTT) to assess insulin were performed in these patients. A CT-scan was used to evaluate visceral (VF) and subcutaneous abdominal fat (SCF). The Central fat distribution index (CDI) was proposed to evaluate the impact of subcutaneous abdominal fat on central fat distribution in hypertensive patients. RESULTS: When compared to NT-NO (n = 17) group, HT-NO (n = 18) showed higher blood pressure levels (systolic and diastolic), greater VF area (84.40 ± 55.70 versus 37.50 ± 23.00 cm²; p = 0.036), greater SCF area (174.30 ± 83.00 versus 79.80 ± 27.40 cm²; p = 0.030), higher HOMAr index (1.59 ± 0.72 versus 0.93 ± 0.48 mmol.mU/L²; p = 0.006), higher CDI index (12.67 ± 7.04 versus 6.19 ± 2.57 cm²/kg) and higher leptin level (19.1 ± 9.6 versus 7.4 ± 3.5 ng/mL; p = 0.028). CONCLUSIONS: Arterial hypertension in non-obese women is associated with insulin resistance, central fat distribution and higher leptin levels.

Sign in / Sign up

Export Citation Format

Share Document